Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jun;51(6):1416-23.
doi: 10.1194/jlr.M002436. Epub 2010 Jan 13.

Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma

Affiliations

Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma

Jodianne T Wood et al. J Lipid Res. 2010 Jun.

Abstract

The endocannabinoid metabolome consists of a growing, (patho)physiologically important family of fatty-acid derived signaling lipids. Diet is a major source of fatty acid substrate for mammalian endocannabinoid biosynthesis. The principal long-chain PUFA found in mammalian brain, docosahexaenoic acid (DHA), supports neurological function, retinal development, and overall health. The extent to which dietary DHA supplementation influences endocannabinoid-related metabolites in brain, within the context of the circulating endocannabinoid profile, is currently unknown. We report the first lipidomic analysis of acute 2-week DHA dietary supplementation effects on the physiological state of 15 fatty-acid, N-acylethanolamine, and glycerol-ester endocannabinoid metabolome constituents in murine plasma and brain. The DHA-rich diet markedly elevated DHA, eicosapentaenoic acid, 2-eicosapentanoylglycerol (EPG), and docosahexanoylethanolamine in both compartments. Dietary DHA enhancement generally affected the synthesis of the N-acyl-ethanolamine and glycerol-ester metabolites to favor the docosahexaenoic and eicosapentaenoic vs. arachidonoyl and oleoyl homologs in both brain and plasma. The greater overall responsiveness of the endocannabinoid metabolome in plasma versus brain may reflect a more circumscribed homeostatic response range of brain lipids to dietary DHA supplementation. The ability of short-term DHA enhancement to modulate select constituents of the physiological brain and plasma endocannabinoid metabolomes carries metabolic and therapeutic implications.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Multiple reaction monitoring LC-MS chromatograms of the metabolite standards and physiological endocannabinoid metabolome constituents analyzed in mouse plasma and brain.
Fig. 2.
Fig. 2.
Fatty acid levels in brain and plasma. Plotted values are log transformations of ng/g brain and ng/ml plasma for each individual animal. The number of stars represents the significance of the mean differences for each metabolite between animals fed the control versus the DHA-supplemented diet for each respective compartment examined; one to three stars represent t-test P-values < 0.05, 0.01, and 0.001, respectively.
Fig. 3.
Fig. 3.
N-acyl-ethanolamine levels in brain and plasma. Plotted values are log transformations of ng/g brain and ng/ml plasma for each individual animal. The number of stars represents the significance of the mean differences for each metabolite between animals fed the control versus the DHA-supplemented diet for each respective compartment examined; one to three stars represent t-test P-values < 0.05, 0.01, and 0.001, respectively.
Fig. 4.
Fig. 4.
Glycerol-ester levels in brain and plasma. Plotted values are log transformations of ng/g brain and ng/ml plasma for each individual animal. The number of stars represents the significance of the mean differences for each metabolite between animals fed the control versus DHA-supplemented diet for each respective compartment examined; one to three stars represent t-test P-values < 0.05, 0.01, and 0.001, respectively.

Similar articles

Cited by

References

    1. De Petrocellis L., Di Marzo V. 2009. An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract. Res. Clin. Endocrinol. Metab. 23: 1–15. - PubMed
    1. Kano M., Ohno-Shosaku T., Hashimotodani Y., Uchigashima M., Watanabe M. 2009. Endocannabinoid-mediated control of synaptic transmission. Physiol. Rev. 89: 309–380. - PubMed
    1. Hwang J., Adamson C., Butler D., Janero D. R., Makriyannis A., Bahr B. A. 2010. Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality. Life Sci. 86: 615–623. - PMC - PubMed
    1. Bradshaw H. B., Walker J. M. 2005. The expanding field of cannabimimetic and related lipid mediators. Br. J. Pharmacol. 144: 459–465. - PMC - PubMed
    1. Karanian D. A., Brown Q. B., Makriyannis A., Kosten T. A., Bahr B. A. 2005. Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity. J. Neurosci. 25: 7813–7820. - PMC - PubMed

Publication types

MeSH terms